#United States #Class Action #New Orleans #Kahn Swick #Pacira BioSciences

Investment Alert: Legal Action Against Pacira BioSciences

In a significant update for investors, Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., has issued a reminder regarding an ongoing class action lawsuit against Pacira BioSciences, Inc. (NASDAQ: PCRX). This lawsuit is particularly relevant for individuals who incurred losses exceeding $100,000 during the specified time frame. Investors must submit their lead plaintiff applications by March 14, 2025, in order to be considered for participation in the lawsuit.

Background of the Lawsuit

The class action targets Pacira and certain executives for allegedly failing to disclose essential information during the defined class period spanning from August 2, 2023, to August 8, 2024. These omissions are alleged violations of federal securities laws, which have led to widespread financial repercussions for many shareholders.

A notable event occurred on August 9, 2024, when Pacira announced the results of its litigation against eVenus, concerning patent rights related to the company's Exparel product. This product is crucial for Pacira, generating about 80% of its revenue. Unfortunately, the court ruled that Pacira's U.S. Patent No. 11,033,495 was invalid, thereby confirming that eVenus did not infringe upon any patent rights. As a consequence of this news, Pacira's stock price plummeted by over 47%, a dramatic fall from $22.36 per share on August 8, 2024, to a low of $11.70 the following day.

Next Steps for Investors

If you purchased Pacira's securities during the specified period and wish to discuss your potential legal options or learn more about the implications of this case, KSF offers a free consultation. You can contact Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or by email at [email protected]. For those interested in becoming the lead plaintiff in this class action, it is vital to file a petition with the courts by the March deadline.

About Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC is recognized as one of the leading boutique securities litigation firms in the United States. The firm caters to a diverse clientele, including public institutional investors, hedge funds, and retail investors, seeking to recover losses stemming from corporate misrepresentation or malfeasance. KSF maintains a strong presence across several states, including New York, Delaware, California, Louisiana, Chicago, and New Jersey.

This lawsuit against Pacira BioSciences illustrates the importance of due diligence when investing in securities. Investors should remain informed and proactive regarding their investments, especially in situations involving substantial financial losses due to alleged corporate misconduct.

For further information regarding this case or Kahn Swick & Foti, please visit www.ksfcounsel.com.